Search results
-
ESMO 2024 – Scorpion joins Relay in the alpha club
ESMO 2024 – Scorpion joins Relay in the alpha club …
- 09/18/2024 - 21:45 -
ESMO 2024 – J&J eyes Rybrevant colorectal expansion
ESMO 2024 – J&J eyes Rybrevant colorectal expansion …
- 09/16/2024 - 12:28 -
ESMO 2024 – a role for immunotherapy in ovarian cancer
ESMO 2024 – a role for immunotherapy in ovarian cancer …
- 09/15/2024 - 21:18 -
ESMO 2024 – combos could be the way forward for CDK2
ESMO 2024 – combos could be the way forward for CDK2 … Pfizer Blueprint Medicines Presentation ESMO 2024 ESMO 2024 ASCO 2023 ASCO 2024 Study Ph1 …
- 09/15/2024 - 21:18 -
ESMO 2024 – Keytruda/Lenvima leap... up to a point
ESMO 2024 – Keytruda/Lenvima leap... up to a point …
- 09/15/2024 - 15:51 -
ESMO 2024 – Opdualag comes under fire
ESMO 2024 – Opdualag comes under fire …
- 09/15/2024 - 08:35 -
ESMO 2024 – Astra’s B7-H4 effort underwhelms
ESMO 2024 – Astra’s B7-H4 effort underwhelms … inhibitor 8 Ph1/2 in solid tumours ESMO 2024: ORR 20% (9/44 PRs) in ≥1.6mg/kg; incl 25% (3/12 …
- 09/15/2024 - 08:35 -
ESMO 2024 – iTeos TIGIT meets its efficacy criteria
ESMO 2024 – iTeos TIGIT meets its efficacy criteria …
- 09/15/2024 - 08:34 -
ESMO 2024 – Nuvalent looks beyond its late-line Alkove
ESMO 2024 – Nuvalent looks beyond its late-line Alkove … ALK+ solid tumours Triple meeting 2023 ESMO 2024 presentation Cutoff date 8 Aug 2023 … treated ROS1+ NSCLC Triple Meeting 2022 ESMO 2024 presentation Cutoff date 13 Sep 2022 …
- 09/15/2024 - 08:34 -
ESMO 2024 – MediLink impresses in small-cell lung cancer
ESMO 2024 – MediLink impresses in small-cell lung cancer …
- 09/14/2024 - 14:22
